Table 1.

Baseline characteristics.

Cohort A (MSI-H)Cohort B (MSS)
Characteristics(n = 10, %)(n = 40, %)
Median age, years (range)53 (30–77)63 (25–79)
Sex
 Male5 (50.0)17 (42.5)
 Female5 (50.0)23 (57.5)
ECOG PS
 010 (100)34 (85.0)
 10 (0)6 (15.0)
Primary site
 Right-sided colon10 (100)27 (67.5)
 Left-sided colon0 (0)13 (32.5)
Metastatic organ
 Liver2 (20.0)28 (70.0)
 Lung2 (20.0)29 (72.5)
 Lymph node7 (70.0)17 (42.5)
 Peritoneum7 (70.0)12 (30.0)
Number of prior chemotherapy
 ≤26 (60.0)12 (30.0)
 ≥34 (40.0)28 (70.0)
Prior regimens
 Fluoropyrimidine10 (100)40 (100)
 Oxaliplatin10 (100)40 (100)
 Irinotecan10 (100)40 (100)
 Angiogenesis inhibitor9 (90.0)40 (100)
 Anti-EGFR inhibitor2 (20.0)17 (42.5)
 Regorafenib1 (10.0)17 (42.5)
 TAS-1020 (0)23 (57.5)
RAS status
 Wild-type5 (50.0)14 (35.0)
 Mutant5 (50.0)25 (62.5)
 Unknown0 (0)1 (2.5)
BRAF V600E status
 Wild-type5 (50.0)28 (70.0)
 Mutant2 (20.0)2 (5.0)
 Unknown3 (30.0)10 (25.0)
MSI or MMR status
 MSI-high or MMR-deficient10 (100)0 (0)
 MSS or MMR-proficient0 (0)40 (100)
  • Abbreviation: ECOG, Eastern Cooperative Oncology Group.